is glp 1 patented How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments Competing in the Post-Patent GLP-1

GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation

Important considerations include: Tirzepatide is not indicated for type 1 diabetes or diabetic ketoacidosis and is not a substitute for insulin No dose adjustment is required in renal impairment, but patients should be monitored for dehydration risk, particularly with significant gastrointestinal side effects Caution is advised in patients with a history of pancreatitis Warnings and precautions apply for patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 Prescribing in primary care requires initiation at 2.5 mg once weekly for 4 weeks (a non-therapeutic starting dose to improve tolerability), then escalation to 5 mg weekly

Beyond the caloric effects, they've PIMPLE PATCHES REVIEW

Hormone Metab Res (2004) 36:7615